EUVIMEDDescoperă EUVIMED
Open access · CC BY-NC-ND 4.0

The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and pancreatic carcinogenesis

Manon Brunet, Claire Vargas, Marjorie Fanjul, Damien Varry, Naïma Hanoun, Dorian Larrieu, Laetitia Pieruccioni, Guillaume Labrousse, Hubert Lulka, Florence Capilla, Alban Ricard, Janick Selves and 6 more

The Journal of Pathology · 2024-08 · 263 (4-5) · 466-481

DOI: 10.1002/path.6298 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2024-06-25. Written by Manon Brunet and 17 co-authors. Institution: CRCT, Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France. Major MEDLINE topics: Pancreatic Neoplasms, Acinar Cells, Ubiquitin-Protein Ligases, Carcinoma, Pancreatic Ductal. Cited 5 times so far (Crossref); 74 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Ecole Normale Supérieure, Association Française pour la Recherche sur le Cancer du Pancréas, Fondation Toulouse Cancer Santé.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

The E3 ubiquitin ligase thyroid hormone receptor interacting protein 12 (TRIP12) has been implicated in pancreatic adenocarcinoma (PDAC) through its role in mediating the degradation of pancreas transcription factor 1a (PTF1a). PTF1a is a transcription factor essential for the acinar differentiation state that is notably diminished during the early steps of pancreatic carcinogenesis. Despite these findings, the direct involvement of TRIP12 in the onset of pancreatic cancer has yet to be established. In this study, we demonstrated that TRIP12 protein was significantly upregulated in human pancreatic preneoplastic lesions. Furthermore, we observed that TRIP12 overexpression varied within PDAC samples and PDAC‐derived cell lines. We further demonstrated that TRIP12 was required for PDAC‐derived cell growth and for the expression of E2F‐targeted genes. Acinar‐to‐ductal cell metaplasia (ADM) is a reversible process that reflects the high plasticity of acinar cells. ADM becomes irreversible in the presence of oncogenic Kras mutations and leads to the formation of preneoplastic lesions. Using two genetically modified mouse models, we showed that a loss of TRIP12 prevented acini from developing ADM in response to pancreatic injury. With two additional mouse models, we further discovered that a depletion of TRIP12 prevented the formation of Kras G12D ‐induced preneoplastic lesions and impaired metastasis formation in the presence of mutated Kras G12D and Trp53 R172H genes. In summary our study identified an overexpression of TRIP12 from the early stages of pancreatic carcinogenesis and proposed this E3 ubiquitin ligase as a novel regulator of acinar plasticity with an important dual role in initiation and metastatic steps of PDAC. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Pancreatic NeoplasmsAcinar CellsUbiquitin-Protein LigasesCarcinoma, Pancreatic DuctalAnimalsHumansMetaplasiaCell PlasticityCarcinogenesisMiceCell Line, TumorCell ProliferationMice, KnockoutGene Expression Regulation, NeoplasticPrecancerous ConditionsCell Transformation, NeoplasticCarrier Proteins

Author keywords

E3 ubiquitin ligaseTRIP12acinar‐to‐ductal metaplasiapancreatic cancerpreneoplastic lesionsthyroid hormone receptor interacting protein 12

Substances

Ubiquitin-Protein LigasesTRIP12 protein, humanCarrier Proteins

Authors and institutions

  • CRCT, Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.
  • Institut National de la Santé et de la Recherche Médicale (INSERM), U1297, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France.
  • Centre de recherches RESTORE, Université de Toulouse, INSERM, CNRS, EFS, ENVT, Toulouse, France.
  • Service d'Histopathologie expérimentale, INSERM US006-CREFRE, Toulouse, France.
  • Département de Pathologie, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
  • Département de Pathologie Beaujon-Bichat, Hôpital Bichat, APHP and Université Paris Cité, Paris, France.

ORCID profiles: Jérôme Torrisani

Funding

  • Ecole Normale Supérieure
  • Association Française pour la Recherche sur le Cancer du Pancréas
  • Fondation Toulouse Cancer Santé
  • Université Toulouse III - Paul Sabatier (University Paul Sabatier)
  • Cancéropôle Grand Sud-Ouest
  • Ligue Contre le Cancer

Cite

APA

Brunet, M., Vargas, C., Fanjul, M., Varry, D., Hanoun, N., Larrieu, D., Pieruccioni, L., Labrousse, G., Lulka, H., Capilla, F., Ricard, A., Selves, J., Couvelard, A., Gigoux, V., Cordelier, P., Guillermet-Guibert, J., Dufresne, M., & Torrisani, J. (2024). The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and pancreatic carcinogenesis. The Journal of Pathology, 263(4-5), 466-481. https://doi.org/10.1002/path.6298

Vancouver

Brunet M, Vargas C, Fanjul M, Varry D, Hanoun N, Larrieu D, et al. The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and pancreatic carcinogenesis. The Journal of Pathology. 2024;263(4-5):466-481. doi:10.1002/path.6298

BibTeX
@article{Brunet2024,
  author = {Brunet, Manon and Vargas, Claire and Fanjul, Marjorie and Varry, Damien and Hanoun, Naïma and Larrieu, Dorian and Pieruccioni, Laetitia and Labrousse, Guillaume and Lulka, Hubert and Capilla, Florence and Ricard, Alban and Selves, Janick and Couvelard, Anne and Gigoux, Véronique and Cordelier, Pierre and Guillermet-Guibert, Julie and Dufresne, Marlène and Torrisani, Jérôme},
  title = {The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and pancreatic carcinogenesis},
  journal = {The Journal of Pathology},
  year = {2024},
  volume = {263},
  number = {4-5},
  pages = {466--481},
  doi = {10.1002/path.6298}
}
Start for free →